Future Diagnostics sold for $13.5 million:
This article was originally published in Clinica
Executive Summary
Primadex Health Systems is to sell its Future Diagnostics subsidiary to Preferred Health Management for $13.5 million. Future Diagnostics co-ordinates the provision of diagnostic imaging services for health plans, insurance companies and other paying entities. The deal does not include Future Diagnostics' medical management services, which are retained by Primadex. Future Diagnostics was purchased by Primadex in 1995 for $3.2 million.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.